DDInter1421 DDInter1376
The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pentazocine {u} (Compound) resembles {v} (Compound) Levallorphan
Pentazocine {u} (Compound) resembles {v} (Compound) Levorphanol
Pentazocine {u} (Compound) binds {v} (Gene) SIGMAR1
Pentazocine {u} (Compound) is included by {v} (Pharmacologic Class) Competitive Opioid Antagonists
Pentazocine {u} (Compound) causes {v} (Side Effect) Cardiovascular insufficiency
Pentazocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Pentazocine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Pentazocine {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Pentazocine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Pentazocine (Compound) resembles Levallorphan (Compound)
Pentazocine (Compound) resembles Levorphanol (Compound)
Pentazocine (Compound) binds SIGMAR1 (Gene)
Pentazocine (Compound) is included by Competitive Opioid Antagonists (Pharmacologic Class)
Pentazocine (Compound) causes Cardiovascular insufficiency (Side Effect)
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Pentazocine may lead to a major life threatening interaction when taken with Iohexol
Pentazocine may lead to a major life threatening interaction when taken with Fenfluramine